Analyst firms · Piper Sandler · CTMX

Piper Sandler CTMX price target and rating history

CytomX Therapeutics Inc. (CTMX) · Health Care

Piper Sandler rates CytomX Therapeutics Inc. (CTMX) Overweight with a $2.50 price target, as of its latest action on Apr 14, 2025. It has published 3 rating actions on CTMX since July 2022, including 1 upgrade and 1 downgrade.

Current rating
Overweight
Price target
$2.50
Median target, all firms
Too few
Actions on CTMX
3

Piper Sandler price target on CTMX

$3.50$2.50$1.502023202420252026
Piper Sandler price target on CTMX, each point a stated target, July 2022 to April 2025.

Every Piper Sandler rating on CTMX

How other firms rate CTMX

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Wolfe ResearchOutperform$6May 19, 2026
GuggenheimBuy$10Jan 20, 2026

Questions about Piper Sandler and CTMX

What is Piper Sandler's price target for CTMX?
Piper Sandler's latest stated price target for CytomX Therapeutics Inc. (CTMX) is $2.50, from its action on Apr 14, 2025.
What is Piper Sandler's rating on CTMX?
Piper Sandler rates CTMX Overweight, a bullish rating, as of Apr 14, 2025.
When did Piper Sandler last change its view on CTMX?
On Apr 14, 2025, Piper Sandler resumes coverage at Overweight, price target $3.25 to $2.50.

All Piper Sandler ratingsCTMX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.